Solid Biosciences Inc. Depreciation
Solid Biosciences Inc. (SLDB) reported Depreciation of $2.58 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2024-03-13
- Solid Biosciences Inc. depreciation for the quarter ending 2023-12-31 was $587.00K, a 8.91% increase year-over-year.
- Solid Biosciences Inc. depreciation for the quarter ending 2023-09-30 was $588.00K, a 34.25% increase year-over-year.
- Solid Biosciences Inc. depreciation for the quarter ending 2023-06-30 was $703.00K, a 2.63% decline year-over-year.
- Solid Biosciences Inc. depreciation for the quarter ending 2023-03-31 was $703.00K, a 0.85% decline year-over-year.
- Solid Biosciences Inc. depreciation for fiscal 2023 was $2.58M, a 7.18% increase from fiscal 2022.
- Solid Biosciences Inc. depreciation for fiscal 2022 was $2.41M, a 18.76% decline from fiscal 2021.
- Solid Biosciences Inc. depreciation for fiscal 2021 was $2.96M, a 24.43% decline from fiscal 2020.
- Solid Biosciences Inc. depreciation for fiscal 2020 was $3.92M, a 38.88% increase from fiscal 2019.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2023-12-31 | $587.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $1.18M derived: sum of 2 quarters · filed 2024-03-13 | $1.88M derived: sum of 3 quarters · filed 2024-03-13 | $2.58M 10-K · filed 2024-03-13 |
| 2023-09-30 | $588.00K 10-Q · filed 2023-11-08 | $1.29M derived: sum of 2 quarters · filed 2023-11-08 | $1.99M 10-Q · filed 2023-11-08 | $2.53M derived: sum of 4 quarters · filed 2024-03-13 |
| 2023-06-30 | $703.00K 10-Q · filed 2023-08-14 | $1.41M 10-Q · filed 2023-08-14 | $1.95M derived: sum of 3 quarters · filed 2024-03-13 | $2.38M derived: sum of 4 quarters · filed 2024-03-13 |
| 2023-03-31 | $703.00K 10-Q · filed 2023-05-11 | $1.24M derived: sum of 2 quarters · filed 2024-03-13 | $1.68M derived: sum of 3 quarters · filed 2024-03-13 | $2.40M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-12-31 | $539.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $977.00K derived: sum of 2 quarters · filed 2024-03-13 | $1.70M derived: sum of 3 quarters · filed 2024-03-13 | $2.41M 10-K · filed 2024-03-13 |
| 2022-09-30 | $438.00K 10-Q · filed 2023-11-08 | $1.16M derived: sum of 2 quarters · filed 2023-11-08 | $1.87M 10-Q · filed 2023-11-08 | $2.63M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | $722.00K 10-Q · filed 2023-08-14 | $1.43M 10-Q · filed 2023-08-14 | $2.19M derived: sum of 3 quarters · filed 2024-03-13 | $2.94M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | $709.00K 10-Q · filed 2023-05-11 | $1.47M derived: sum of 2 quarters · filed 2024-03-13 | $2.22M derived: sum of 3 quarters · filed 2024-03-13 | $2.94M derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | $760.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $1.51M derived: sum of 2 quarters · filed 2024-03-13 | $2.23M derived: sum of 3 quarters · filed 2024-03-13 | $2.96M 10-K · filed 2024-03-13 |
| 2021-09-30 | $752.00K 10-Q · filed 2022-11-10 | $1.47M derived: sum of 2 quarters · filed 2022-11-10 | $2.20M 10-Q · filed 2022-11-10 | $3.00M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-06-30 | $718.00K 10-Q · filed 2022-08-11 | $1.45M 10-Q · filed 2022-08-11 | $2.25M derived: sum of 3 quarters · filed 2023-03-23 | $3.01M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-03-31 | $734.00K 10-Q · filed 2022-04-27 | $1.53M derived: sum of 2 quarters · filed 2023-03-23 | $2.30M derived: sum of 3 quarters · filed 2023-03-23 | $3.63M derived: sum of 4 quarters · filed 2023-03-23 |
| 2020-12-31 | $796.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $1.56M derived: sum of 2 quarters · filed 2023-03-23 | $2.90M derived: sum of 3 quarters · filed 2023-03-23 | $3.92M 10-K · filed 2023-03-23 |
| 2020-09-30 | $766.00K 10-Q · filed 2020-11-05 | $2.10M derived: sum of 2 quarters · filed 2020-11-05 | $3.13M 10-Q · filed 2021-11-03 | $3.93M derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-06-30 | $1.33M 10-Q · filed 2020-08-06 | $2.36M 10-Q · filed 2021-08-16 | $3.17M derived: sum of 3 quarters · filed 2022-03-14 | $3.93M derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-03-31 | $1.03M 10-Q · filed 2021-05-14 | $1.83M derived: sum of 2 quarters · filed 2022-03-14 | $2.60M derived: sum of 3 quarters · filed 2022-03-14 | $3.25M derived: sum of 4 quarters · filed 2022-03-14 |
| 2019-12-31 | $806.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $1.57M derived: sum of 2 quarters · filed 2022-03-14 | $2.23M derived: sum of 3 quarters · filed 2022-03-14 | $2.82M 10-K · filed 2022-03-14 |
| 2019-09-30 | $764.00K 10-Q · filed 2020-11-05 | $1.42M derived: sum of 2 quarters · filed 2020-11-05 | $2.02M 10-Q · filed 2020-11-05 | $2.50M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-06-30 | $658.00K 10-Q · filed 2020-08-06 | $1.25M 10-Q · filed 2020-08-06 | $1.74M derived: sum of 3 quarters · filed 2021-03-15 | $2.28M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-03-31 | $596.00K 10-Q · filed 2020-05-07 | $1.08M derived: sum of 2 quarters · filed 2021-03-15 | $1.62M derived: sum of 3 quarters · filed 2021-03-15 | $1.94M derived: sum of 4 quarters · filed 2021-03-15 |
| 2018-12-31 | $481.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $1.03M derived: sum of 2 quarters · filed 2021-03-15 | $1.34M derived: sum of 3 quarters · filed 2021-03-15 | $1.57M 10-K · filed 2021-03-15 |
| 2018-09-30 | $545.00K 10-Q · filed 2019-11-12 | $858.00K derived: sum of 2 quarters · filed 2019-11-12 | $1.08M 10-Q · filed 2019-11-12 | $1.31M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $313.00K 10-Q · filed 2019-08-14 | $540.00K 10-Q · filed 2019-08-14 | $763.00K derived: sum of 3 quarters · filed 2020-03-12 | $873.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $227.00K 10-Q · filed 2019-05-13 | $450.00K derived: sum of 2 quarters · filed 2020-03-12 | $560.00K derived: sum of 3 quarters · filed 2020-03-12 | $624.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $223.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $333.00K derived: sum of 2 quarters · filed 2020-03-12 | $397.00K derived: sum of 3 quarters · filed 2020-03-12 | $448.00K 10-K · filed 2020-03-12 |
| 2017-09-30 | $110.00K 10-Q · filed 2018-11-13 | $174.00K derived: sum of 2 quarters · filed 2018-11-13 | $225.00K 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $64.00K 10-Q · filed 2018-08-10 | $115.00K 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | $51.00K 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $56.00K 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |